64Cu-LLP2A Imaging in Multiple Myeloma

Phase 1, open-label trial of 64cu-llp2a in multiple myeloma (MM) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoints: Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A, Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the number of participants who experience an adverse event related to 64Cu-LLP2A and 3 more. Started Nov 2018; status: terminated.